Developing a clinical diabetes guideline in diabetes research network in Iran

Iranian Journal of Public Health

Volumn 43, Issue 6, 2014, Pages 713-721

  Nasli Esfahani, Ensieh ^a   Peimani, Maryam ^a   Rambod, Camelia ^a   Omidvar, Maryam ^a   Larijani, Bagher ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Clinical guidelines; Diabetes; Diabetes network; Iran

Indexed keywords

EID: 84903515397     PISSN: 22516085     EISSN: 22516093     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Xu Y, Wang L, He J, Bi Y, Li M, Wang T, et al. (2013). Prevalence and control of diabetes in Chineseadults. JAMA, 310(9): 948-59.
2. Magliano DJ, Soderberg S, Zimmet PZ, Chen L, Joonas N, Kowlessur S, et al. (2012). Explain-ing the increase of diabetes prevalence and plasma glucose in Mauritius. Diabetes Care, 35: 87-91.
3. World Health Organization, global status report on noncommunicable diseases 2010, 2011.
4. Azimi-Nezhad M, Ghayour-Mobarhan M, Pariza-deh MR, Safarian M, Esmaeili H, Parizadeh SM, et al. (2008). Prevalence of type 2 diabetes mellitus in Iran and its relationship with gen-der, urbanization, education, marital status and occupation. Singapore Med J, 49(7): 571-6.
5. Esteghamati A, Gouya MM, Abbasi M, Delavari A, Alikhani S, Alaedini F, et al (2008). Preva-lence of diabetes and impaired fasting glucose in the adult population of Iran: national survey of risk factors for non-communicable diseases of Iran. Diabetes Care, 31(1): 96-8.
6. Karami M, Khalili D, Eshrati B (2012). Estimat-ing the proportion of diabetes to the attributa-ble burden of cardiovascular diseases in Iran. IranianJPubl Health, 41(8): 50-55.
7. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, et al. (2011). Guideline and recommendations for labora-tory analysis in the diagnosis and management of diabetes mellitus. Clin. Chem, 57(6): e1-e47.
8. Larme AC, Pugh JA (1998). Attitudes of primary care providers toward diabetes. Diabetes Care, 21(9): 1391-6.
9. Esteghamati A, Khalilzadeh O, Anvari M, Meysamie A, Abbasi M, Forouzanfar M, Alaeddini F (2009). The economic costs of diabetes: a population-basedstudy in Tehran, Iran. Diabetologia, 52(8): 1520-27.
10. Golozar A, Khademi H, Kamangar F, Poutschi H, Islami F, Abnet CC, et al (2011). Diabetes mellitus and its correlates in an Iranian adult population. PLoS One, 6(10): e26725.
11. Azizi F, Gouya MM, Vazirian P, Dolatshahi P, Habibian H (2003). Screeningfor type 2 diabe-tes in the iranian national programm: a prelimi-nary report. East Mediterr Health J, 9(5, 6):1122-7.
12. Tol A, Pourreza A, Shojaeezadeh D, Mahmoodi M, Mohebbi B (2012). The assessment of relations between socioeconomic status and number of complications among type 2 diabetic patients. Iranian J Publ Health, 41(5): 66-72.
13. Yarahmadi SH, Etemad K, MahdaviHazaveh AR, Azhang N (2013). Urbanization and non-communicable risk factors in the capital city of 6 big provinces of Iran. IranianJPubl Health, 42(suppl.1): 113-18.
14. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. (2012). Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetologia, 55: 1577-96.
15. The National Collaborating Centre for Chronic Conditions. Type 2 diabetes: National clinical guideline for management in primary and secondary care (update). London: royal College of physicians, 2008. Available at: www.nice.org.uk/CG87shortguideline
16. Kim TH, Chun KH, Kim HJ, Han SJ, Kim DJ, Kwak J, et al. (2012). Direct medical costs for patients with type 2 diabetes and related com-plications: A prospective cohort study based on the Korean national diabetes program. J Korean Med Sci, 27: 876-82.
17. Tabatabaei-Malazy O, Peimani M, Heshmat R, Pajouhi M (2011). Status of diabetes care in el-derly diabetic patients of a developing country. Iranian Journal of Diabetes and Lipid Disor-ders, 10:1-8.
18. Delavari A, Alikhani S, Nili S, Birjandi RH, Bir-jandi F (2009). Quality of care of diabetes mellitus type 2 patients in Iran. Arch Iranian Med, 12(5): 492-95.
19. Coffey RM, Matthews T (2004). Diabetes care quality improvement: a resource guide for state action. Rockville, MD: AHRQ publication, No.04-0072.
20. Hadipour M, Abolhasani F, Molavi-Vardanjani H (2013). Health related quality of life in patients with of type II diabetes in Iran. Payesh (Journal of the Iranian Institute for Health Sciences Research), 12(2): 135-41.
21. Bergsteinsson JI (2013). A checklist-based guide-line system for implementing clinical guidelines into practice. A masterś thesis in biomedical engineering and informatics. School of Medi-cine and Health Aalborg University, Denmark. http://www.smh.aau.dk
22. Grimshaw JM, Thomas RE, Maclennan G, Fraser C, Ramsay CR, Vale L, et al. (2004). Effective-ness and efficiency of guideline dissemination and implementation strategies (Executive sum-mary). Health Technol Assess, 8(6): 1-72.
23. Lugtenberg M, Zegers-van Schaick JM, Westert GP, Burgers JS (2009). Why don't physicians adhere to guideline recommendations in prac-tice? An analysis of barriers among Dutch gen-eral practitioners. Implement Sci, 4: 54. doi:10.1186/1748-5908-4-54
24. Wyatt KD, Stuart LM, Brito JP, Carranza Leon B, Domecq JP, Prutsky GJ, et al. (2013). Out of context: clinical practice guidelines and patients with multiple chronic conditions: asystematic review. Med Care. doi: http://dx.doi.org/10.1097/MLR.0b013e3182a51b3d [Epub ahead of print].
25. Holmer HK, Ogden LA, Burda BU, Norris SL (2013). Quality of clinical practice guideline for glycemic control in type 2 diabetes mellitus. Plos One, 8(4): e58625.
26. Bennett WL, Odelola OA, Wilson LM, Belon S, Selvaraj S, Robinson KA, et al. (2012). Evalua-tion of guideline recommendations on oral medications for type 2 diabetes mellitus: a systematic review. Ann Intern Med, 156: 27-36.
27. Yawn BP, Akl EA, Qaseem A, Black P, Campos-Outcalt D (2012). Identifying target audiences: who are the guidelines for? Proc Am Thorac Soc, 9(5): 219-24.
28. Raz I (2013). Guideline approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care, 36(suppl.2): S139-S144.
29. Gagliardi AR, Brouwers MC, Palda VA, Lemieux-charles L, Grimshaw JM (2011). How can we improve guideline use? A conceptual framework of implementability. Implement Sci, 6: 26.
30. Handelsman Y, Mechanick JI, Blonde L, Grun-berger G, Bloomgarden ZT, Bray GA, et al. (2011). American association of clinical endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract, 17(suppl 2):1-53.
31. Home P, Hadad J, Latif ZA, Soewondo P, Benabbas Y, Litwak L, et al. (2013). Compari-son of national/ regional diabetes guidelines for the management of blood glucose control in non-western countries. Diabetes Ther, 4: 91-102.
32. Karamat MA, Syed A, Hanif W (2010). Review of diabetes management and guidelines during Ramadan. J R Soc Med, 103:139-47.
33. Pathan MF, Sahay RK, Zargar AH, et al. (2012). South Asian consensus guideline: use of insulin in diabetes during ramadan. Indian J EndocrinolMetab, 6: 499-502.
34. Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K (2007). The burden and costs of chronic diseases in low-income and middle-in-come countries. Lancet, 370: 1929-38.
35. Yazdizadeh B, Majdzadeh R, Salmasian H (2010). Systematic review of methods for evaluating healthcare research economic impact. Health Res PolicySyst, 8: 6.
36. Mackey TK, Liang BA (2011). The role of prac-tice guidelines in medical malpractice litigation. AmMed Assoc J Ethics, 13(1): 36-41.
37. Hager KK, Loprinzi P, Stone D (2013). Implementing diabetescare guidelines in long term care. J Am Med Dir Assoc. doi: 10.1016/j.jamda.2013.05.020.[Epub ahead of print].